Table 3.
Clinical and biomedical variables in DLB patients by the duration of cognitive impairment at presentation.
| Clinical variables, Mean ± SD or % | Biochemical variables, Mean ± SD | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tertile of duration of cognitive impairment, Y | MMSE score | NPI score | CFL | VH | RBD | PARK | tHcy (μmol/L) | Folate (nmol/L) | VitaminB12 (pmol/L) |
| I<2 | 17.1 ± 6.9 | 16.9 ± 16.0 | 78.90% | 68.40% | 68.40% | 73.00% | 31.6 ± 25.5 | 7.4 ± 3.9 | 299.2 ± 246.6 |
| II 2–4 | 15.3 ± 6.8 | 20.1 ± 17.9 | 80.90% | 76.10% | 65.50% | 52.30% | 21.7 ± 12.8 | 7.3 ± 6.2 | 322.3 ± 190.2 |
| III >4 | 13.5 ± 9.5 | 21.0 ± 14.7 | 90.90% | 77.20% | 54.50% | 54.40% | 24.0 ± 17.8 | 9.9 ± 5.0 | 349.6 ± 213.5 |
| P value | 0.003 | <0.001 | 0.305 | 0.553 | 0.662 | 0.181 | 0.196 | <0.001 | <0.001 |
Results are shown as the mean ± the standard deviation for analyses of variance. DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination; Hcy, homocysteine; NPI, neuropsychiatric inventory; CFL, cognitive fluctuation; VH, visual hallucination; RBD, rapid eye movement (REM) sleep behavior disorder; PARK, Parkinsonism.